LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
LFCR$6.37+0.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Accrued expenses and other current liabilities
- Accrued expenses and other current liabilities
The following table presents the components of accrued expenses and other current liabilities:
| September 30, 2025 | May 25,2025 | |
|---|---|---|
| Accrued payable to Redeemable Convertible Preferred Stockholders | $4,664 | $4,499 |
| Accrued compensation | 4,157 | 6,144 |
| Contract liabilities, related party | 4,131 | 2,731 |
| Contract liabilities | 3,083 | 684 |
| Current portion of debt, related party | 773 | 773 |
| Current portion of debt | 174 | 2,664 |
| Accrued customer pass-through expenditures | — | 1,911 |
| Other | 2,861 | 2,552 |
| Accrued expenses and other current liabilities | $19,843 | $21,958 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.